

Claims

1. Use of montelukast or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a condition characterized by inflammation and/or wounding in a patient that has, or is vulnerable to, a suppressed immune system, wherein the immunosuppression is brought on by radiation therapy administered during the treatment of a disorder, wherein the radiation therapy is targeted to the lower abdomen.
2. The use as claimed in Claim 1, wherein the montelukast or pharmaceutically acceptable salt thereof provides an immunorestorative effect at the same time as promoting recovery and/or healing of wounds that are associated with said condition.
3. The use as claimed in Claim 1 or Claim 2, wherein the montelukast or pharmaceutically acceptable salt thereof provides an antiinflammatory effect without compromising the patient's immune system.
4. The use as claimed in Claim 4, wherein the disorder being treated by the radiation therapy is cancer.
5. The use as claimed in any one of the preceding claims, wherein the condition characterized by inflammation is selected from the group: radiation enteritis, radiation colitis, radiation hepatitis, radiation myelitis, radiation vaginitis and radiation proctitis.
6. The use as claimed in Claim 6, wherein the disorder is radiation proctitis.
7. The use as claimed in Claim 6 or Claim 7, wherein the disorder comprises one or more of the group: acute radiation proctitis, radiation colitis, radiation associated vascular ectasias and/or chronic radiation proctopathy.
8. The use as claimed in any one of the preceding claims wherein the montelukast or pharmaceutically acceptable salt thereof is formulated for local and topical administration.
9. The use as claimed in Claim 9 wherein the montelukast is in the form of a gel.
10. The use as claimed in Claim 9 or Claim 10, wherein the local, topical application is anorectal.

11. The use as claimed in any one of the preceding claims wherein the treatment is of a patient with a compromised immune system.
12. The use as claimed in any one of the preceding claims wherein the treatment restores a normal function of the immune system of a patient.
13. The use as claimed in any one of the preceding claims, wherein the pharmaceutically acceptable salt of montelukast is montelukast sodium.
14. Montelukast, or a pharmaceutically acceptable salt thereof, for use in a method for the treatment of a condition, wherein the treatment and/or the condition are as defined in any one of the preceding claims.